Humacyte, Inc. Long-Term Debt, Maturity, Remainder of Fiscal Year
Humacyte, Inc. (HUMA) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $8.57 million as of 2023-03-31, per its 10-Q filed 2023-05-12.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2023-05-12
- 2023-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $8.57M.
- 2022-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2022-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2022-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2023-03-31 | $8.57M 10-Q · filed 2023-05-12 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-12 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |